New hope for rare ovarian cancer: drug combo tested in japanese patients
NCT ID NCT06682572
First seen Jan 06, 2026 · Last updated Jun 14, 2026 · Updated 19 times
Summary
This study tests two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has come back after platinum-based chemotherapy. The goal is to see if the combination can shrink tumors and control the disease. Participants must have measurable tumors and adequate organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Cancer Center Hospital
Nagoya, Aichi-ken, 464-8681, Japan
-
Jikei University Hospital
Minato, Tokyo, 105-0003, Japan
-
Kurume University Hospital
Kurume, Fukuoka, 830-0011, Japan
-
Mie University Hospital
Tsu, Mie-ken, 514-8507, Japan
-
Tohoku University Hospital
Sendai, Miyagi, 980-8574, Japan
Conditions
Explore the condition pages connected to this study.